Hepatocellular carcinoma (liver cancer)

HCC arises from hepatocytes, the liver’s main working cells, and around four of every five cases worldwide grow in a liver already damaged by chronic disease. The sequence is well understood: decades of injury — from hepatitis B or C, alcohol, or the metabolic fatty liver disease now surging worldwide — drive cycles of cell death and regeneration; regenerating tissue accumulates mutations; nodules form, some progress, and a cancer eventually emerges. Hepatitis B can shortcut the sequence, driving cancer even without cirrhosis because the virus integrates into the cell’s own DNA — the reason surveillance rules for HBV carriers extend beyond cirrhotics.

This origin story gives HCC its defining clinical property: it is a cancer with an identifiable at-risk population, years in advance. Most cancers are found when they cause symptoms; HCC can be WATCHED FOR, with six-monthly ultrasound in a defined group — and the entire difference between the curable and incurable versions of this disease usually comes down to whether that watching happened. Small tumours found on surveillance are treatable by resection, ablation or transplantation with genuinely good outcomes; symptomatic tumours found late seldom are.

The second defining property is the dual disease: every treatment decision must respect not only the tumour but the failing liver around it. A small cancer in a decompensated liver cannot be cut out — the remnant liver would fail — which is precisely where transplantation earns its unique role, replacing the cancerous organ entirely. Staging systems for HCC are therefore unlike other cancers’, grading liver function and patient fitness alongside tumour burden; the Barcelona (BCLC) system, the most widely used, is built exactly this way.

Globally, HCC ranks among the commonest causes of cancer death, with its weight concentrated where its causes are: hepatitis B belts across East Asia and Africa, hepatitis C cohorts, and — increasingly, everywhere — the metabolic pathway. Its epidemiology is shifting rather than shrinking: vaccination and antivirals are slowly deflating the viral share while fatty liver disease inflates the metabolic one.

Decisions in HCC are made by committee by design: the tumour board — hepatologist, transplant and liver surgeons, interventional radiologist, oncologist, radiologist and specialist nurses around one screen — is the standard of care, because the treatment ladder crosses so many specialties that no single clinician can hold the whole map. For patients this has a practical corollary: an opinion on an HCC that has not passed through a multidisciplinary board is an incomplete opinion, and asking “was my case discussed at the board, and what did it conclude?” is among the most clarifying questions in this disease.

Early hepatocellular carcinoma — the curable kind — typically causes no symptoms at all. It grows inside an organ with spare capacity and no pain sensors in its substance, hidden behind symptoms the underlying cirrhosis may already produce. This silence is the whole argument for surveillance: by the time HCC speaks, it has usually grown beyond the stages where cure is straightforward.

When symptoms come, they come in two voices. The tumour’s own: dull or aching pain in the right upper abdomen, sometimes reaching the right shoulder; a felt mass; early satiety and weight loss; fevers without infection. And the liver’s: a previously stable cirrhotic decompensating without other explanation — new ascites, new jaundice, new encephalopathy, or variceal bleeding — which in a surveillance-eligible patient should always prompt the question “has a cancer appeared?”. Rarer presentations include acute pain from bleeding into or from the tumour, and paraneoplastic effects such as unexplained high calcium or low glucose.

Two practical translations. For a person with cirrhosis or chronic hepatitis B: new right-upper-quadrant pain, unexplained weight loss, or any unexplained deterioration deserves imaging promptly, whatever the last surveillance scan showed. For everyone else: the symptom list above is late-stage by nature — the useful action happens years earlier, in getting tested for hepatitis, assessing liver health, and entering surveillance if eligible. In HCC, the meaningful “early symptom” is a risk factor known about and acted on.

One reassurance belongs here, because scans generate it as a question weekly: most lesions found in livers are NOT cancer. Simple cysts and haemangiomas — benign vascular knots — are extremely common incidental findings with characteristic imaging appearances; in a non-cirrhotic liver without risk factors they usually end the conversation at the report. The at-risk liver changes the arithmetic entirely, which is why the same shadow earns a multiphase scan in a hepatitis B carrier and a shrug in a routine check-up. When a benign label is given, believing it is also allowed: a characterised haemangioma needs no annual anxiety, and specialists say so explicitly to prevent scan-cycles nobody needs.

Chronic hepatitis B remains the largest single global cause, responsible for the East Asian and African weight of the disease; risk scales with viral load and duration, runs in infected families, and — uniquely — operates even without cirrhosis, through direct integration of viral DNA into liver-cell genomes. Antiviral suppression lowers the risk substantially without abolishing it, which is why treated carriers stay in surveillance. Chronic hepatitis C built the twentieth-century Western cohort; modern direct-acting antivirals cure the infection and cut subsequent cancer risk sharply — but a cured patient whose liver already reached cirrhosis remains at risk, and remains in surveillance, a rule still too little known. Alcohol-related cirrhosis is the third classical road.

The fourth road is becoming the widest: metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), the liver face of obesity and type 2 diabetes. It drives HCC both through cirrhosis and, in a minority, before it — and because the at-risk population is vast and mostly unaware, an increasing share of metabolic HCC presents outside any surveillance programme. Rarer roads deserve their lines: aflatoxin — a contaminant of poorly stored grain and nuts in parts of Africa and Asia — multiplies hepatitis B risk; haemochromatosis (iron overload), alpha-1 antitrypsin deficiency, autoimmune liver disease and any other route to cirrhosis carry their proportionate risk.

Stating the mechanism plainly dissolves several myths: HCC is not generally hereditary (families share hepatitis B, not a cancer gene); it is not caused by a single dietary sin; and no supplement prevents it. Its causes are large, slow and mostly modifiable at population scale — vaccination, antivirals, alcohol policy, metabolic health — which is why HCC epidemiology tracks public-health history so faithfully.

Other primary liver cancers deserve their boundary lines, since reports use precise names: cholangiocarcinoma (bile-duct cancer) is the second commonest, behaves and is treated differently, and only rarely enters transplant pathways under strict protocols; fibrolamellar carcinoma is a rare young-adult variant arising in HEALTHY livers; and metastases from bowel, breast or pancreas — cancers visiting the liver — outnumber all primary liver tumours combined and follow their original cancer’s playbook. “Liver cancer” in a report is a family name; the first question is always which member.

The risk factors are the causes above compounded by degree and time: cirrhosis of ANY cause is the master risk factor, concentrating the large majority of cases; within hepatitis B, risk rises with age, male sex, viral load, co-infection, family history of HCC and African or Asian birth cohorts; within cured hepatitis C, prior cirrhosis keeps risk alive; in metabolic disease, diabetes and obesity are independent amplifiers; alcohol multiplies whatever it is added to; aflatoxin multiplies hepatitis B specifically; smoking adds measurably.

Guidelines convert these gradients into a surveillance list, and inclusion matters more than nuance: essentially everyone with cirrhosis (of any cause, once liver function is good enough that treatment would be possible), plus defined non-cirrhotic hepatitis B groups — commonly framed as men from higher-incidence regions above certain ages, women likewise, and anyone with a family history of HCC. The programme itself is deliberately simple: liver ultrasound every six months, usually with the blood marker alpha-fetoprotein. Six months is chosen to match the growth rate of small tumours; annual scanning misses that window measurably. For readers, the section reduces to a two-line checklist: if you have cirrhosis, you belong in six-monthly surveillance — ask, and if you carry hepatitis B, ask whether your age, sex, origin or family history places you there too.

HCC staging must answer three questions at once — how much tumour, how good the liver, how fit the patient — because treatment depends on all three. The Barcelona Clinic Liver Cancer (BCLC) framework, used worldwide, does exactly that; its stages map to the treatment ladder below.

HCC is unusual among major cancers in that imaging alone can make the diagnosis. In a cirrhotic liver, a nodule above one centimetre showing the canonical dynamic pattern — bright arterial-phase enhancement followed by washout in later phases — on multiphase CT or MRI meets internationally standardised criteria (the LI-RADS system formalises them) and is treated as HCC without a needle. Biopsy is reserved for atypical images, non-cirrhotic livers, or where systemic-therapy planning wants tissue; the old fear of needle-track seeding is small but real enough to keep biopsy purposeful rather than routine.

The surveillance-to-diagnosis pipeline works in tiers: six-monthly ultrasound (with AFP) finds a candidate lesion or a rising marker; multiphase CT or contrast MRI characterises it; MRI with liver-specific contrast adds sensitivity for the smallest nodules where available. Once cancer is established, staging assembles the three-question picture — chest CT (and bone imaging when indicated) for spread; portal vein assessment for the vascular invasion that changes everything; liver function scored by Child-Pugh and MELD; and fitness assessed for the treatments actually contemplated, up to and including full transplant evaluation. Alpha-fetoprotein, measured throughout, serves as risk marker, treatment-response gauge and — in transplant selection — an increasingly formal criterion, with very high levels flagging aggressive biology that criteria in several systems now exclude or require to fall before listing.

One diagnostic principle deserves bold type for families navigating opinions: the FIRST question in HCC is never “can this tumour be removed?” but “what can this LIVER tolerate?”. Identical scans lead to opposite plans in different livers, and second opinions that ignore the liver half of the file mislead. A complete file — surveillance history, multiphase imaging, AFP trend, liver scores, endoscopy findings — is what lets any centre, anywhere, give a real answer.

One further practical point about scans: quality and comparability matter as much as recency. Multiphase protocols differ between machines, and a lesion characterised on one scanner is best re-imaged, where possible, on comparable protocols — which is why receiving centres ask for the actual images (disc or transfer link), never just the written reports, and why keeping personal copies of every scan is standing advice for anyone in surveillance. The report describes; the images decide.

Biopsy’s modern role is expanding at the margins worth noting: molecular treatment selection and trial entry increasingly want tissue even where imaging sufficed diagnostically, and liquid-biopsy research aims at blood-based detection that may one day complement ultrasound surveillance. For now the practical rule stands — imaging diagnoses most cirrhotic-liver HCC, tissue answers the exceptions and the research questions.

The recurring numbers of an HCC file, and what each is doing there.

HCC’s complications interleave with cirrhosis’s, each worsening the other. The tumour’s own: growth into the portal vein — the signature complication, converting early to advanced stage in one imaging finding, raising portal pressure and seeding spread; rupture and bleeding, an abdominal emergency presenting with sudden pain and shock; bile duct invasion causing obstructive jaundice; and metastasis, most often to lungs, abdominal lymph nodes and bone. Paraneoplastic mischief — high calcium, low glucose, raised red cell counts — occasionally decorates the picture.

The alliance complications matter more day to day: a growing tumour steals functional reserve, so a compensated cirrhotic decompensates — ascites, encephalopathy, variceal bleeding — earlier than the liver alone would dictate; and every treatment spends liver reserve too, which is why complications OF therapy (post-resection liver failure, post-embolisation decompensation) are planned for as carefully as the therapy itself. On the transplant road the characteristic complication is time: tumours can progress beyond criteria while waiting — the reason bridging treatments hold the fort, AFP and imaging are rechecked on schedule, and dropout from the list is tracked as an outcome in its own right. After transplant, recurrence — the residue of biology invisible on scans — remains the principal cancer risk and the reason selection criteria exist at all; it is uncommon within Milan, and surveillance after transplant continues precisely to catch its exceptions early.

Treatment-side effects have their own honest ledger: post-embolisation syndrome — a few days of pain, fever and fatigue after TACE — is common and self-limiting; ablation near the liver surface can inflame the diaphragm (shoulder-tip pain that settles); immunotherapy’s characteristic risks are immune ones — colitis, thyroid and skin effects — monitored on protocol; and the TKIs trade their benefit for hand-foot skin reactions, blood pressure and fatigue that dose adjustment usually tames. Modern HCC care is substantially the craft of keeping these ledgers balanced.

HCC is among the most preventable major cancers, in three layers. Preventing the liver disease: hepatitis B vaccination from birth — already visibly bending cancer curves in early-adopting countries; safe blood and injections; treating hepatitis C with curative antivirals; and the metabolic basics — weight, diabetes control, alcohol within honest limits — that shrink the fatty-liver road. Preventing cancer WITHIN liver disease: antiviral suppression of hepatitis B and cure of hepatitis C each cut subsequent HCC substantially; abstinence changes trajectory in alcohol-related disease; coffee, unusually for nutritional epidemiology, keeps earning cautious guideline mentions as associated with lower risk; aflatoxin control — proper grain storage — matters where exposure is real. No supplement, cleanse or alternative protocol has any comparable evidence, and this platform will not pretend otherwise.

The third layer is the one this page keeps returning to because readers can act on it this month: liver cancer surveillance as secondary prevention. Six-monthly ultrasound with AFP does not lower the chance of developing HCC — it transforms the stage at which it is found, which in this disease is the difference between the curative ladder’s top rungs and its bottom. Every guideline body writes the same sentence in its own words: the commonest fatal error in hepatocellular carcinoma is not a treatment choice but a surveillance absence. If this page has one takeaway for an at-risk reader, it is to ask one question at the next appointment: “Am I in a six-monthly surveillance programme — and if not, why not?”

For those cured of hepatitis C, one paragraph of precision: cure removes the virus, not the history. A liver that reached cirrhosis before cure remains a surveillance liver indefinitely — its cancer risk falls but never rejoins the general population’s — while a liver cured at mild fibrosis usually can leave surveillance. Knowing which side of that line you were on at cure is a single question to a hepatologist, and one of the highest-value facts a cured patient can carry.

Curative rungs. Surgical resection — removing the tumour-bearing segment — suits single tumours in livers with preserved function and without significant portal hypertension; in the right candidates it offers excellent outcomes, with the remnant liver monitored lifelong because new tumours can arise in the same diseased soil. Ablation — destroying tumours in place with radiofrequency or microwave energy through a needle — rivals resection for the smallest lesions and serves both as definitive therapy and as bridge to transplant. Transplantation — the next section’s subject — is the only rung that treats cancer and cirrhosis together.

Liver-directed rungs. Transarterial chemoembolisation (TACE) exploits the tumour’s arterial blood supply, delivering chemotherapy and blocking flow; it is the standard for intermediate-stage disease, a bridge and downstaging tool on the transplant road, and repeatable. Radioembolisation (TARE/Y-90) delivers radiation microspheres by the same route, with growing roles alongside and instead of TACE. Stereotactic radiotherapy earns selective use where needles and catheters cannot go.

Systemic rungs — transformed within the last few years. Immunotherapy combinations now lead: atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, each beat the former standard sorafenib in randomised trials and became first-line options for advanced disease; tyrosine kinase inhibitors (sorafenib, lenvatinib, and later-line regorafenib, cabozantinib) and ramucirumab (in high-AFP disease) remain important, particularly where immunotherapy is contraindicated — including, cautiously, in transplant recipients, where checkpoint inhibitors risk provoking graft rejection and are handled by specialists only. Two cross-cutting rules complete the ladder: the underlying virus is treated alongside the cancer at every rung; and stage migration is expected — patients move down a rung when liver or fitness forbids the ideal, and sometimes UP one, as when downstaging brings a transplant back into reach.

Supportive and palliative care run alongside every rung, not after the last one: pain control, nutrition (muscle preservation measurably affects treatment tolerance), management of the cirrhosis underneath, and honest symptom-focused care when disease outruns treatment — introduced early, it lengthens good time rather than shortening hope. And across all stages, the underlying liver disease keeps its own treatment lane: antivirals continue, alcohol stays stopped, and decompensation is managed as vigorously as the tumour, because in HCC the liver and the cancer are always two patients in one body.

Transplantation holds a place in HCC that it holds in no other solid cancer, for one structural reason: the operation removes not only the tumour but the cirrhotic organ generating tumours. The rules governing that opportunity are the Milan criteria — one tumour up to five centimetres, or up to three tumours none above three, without vascular invasion or spread — validated over nearly three decades as selecting patients whose post-transplant outcomes match non-cancer recipients. Expanded criteria (UCSF and successors) and modern refinements adding AFP and tumour behaviour over time stretch the boundary at experienced centres; “downstaging” protocols use TACE, ablation or radioembolisation to shrink beyond-criteria disease back within it, then demand a period of stability — testing biology, not just size — before listing. Every programme states its own rules; what is universal is that criteria exist because organs are scarce and recurrence wastes them, a hard sentence that selection frameworks exist to make fair.

On the list, HCC runs on modified physics: tumour patients often have low MELD scores (their livers still function), so allocation systems grant standardised exception points that rise with waiting time — while bridging therapy restrains the tumour and scheduled reassessment confirms the criteria still hold; progression beyond them means delisting, the outcome bridging exists to prevent. Living-donor transplantation changes the physics again: no queue, surgery timed to the tumour’s window — a genuine advantage where deceased donation is scarce or waiting long, and the route through which many international patients, including at centres in Türkiye, receive HCC transplants. The trade-offs are the permanent ones of living donation — a healthy person’s operation — plus, at some centres, criteria modestly beyond national deceased-donor rules; the legal and ethical framework this platform documents applies in full, and no reputable centre trades donor safety against tumour urgency.

The file for any transplant opinion: complete multiphase imaging with dates, AFP trend, treatment history with response, current Child-Pugh/MELD, endoscopy findings, virus status and — for living donation — the donor’s independent medical file and documented relationship per destination law. HCC adds one deadline other diagnoses lack: criteria are a moving window, and opinions sought serially while a tumour grows can close it. Parallel, not sequential, inquiry is the organising advice. The liver transplant, living donation and cirrhosis guides carry the pathway details.

HCC’s outlook is really several outlooks, sorted by stage at discovery — which is to say, sorted largely by surveillance. Found very early and treated curatively, five-year survival figures in published series reach ranges that justify the word cure for many patients; transplanted within Milan criteria, recurrence is the exception and long-term survival parallels benign-indication transplants. Intermediate-stage disease managed with modern liver-directed therapy commonly runs a course of years, punctuated by retreatment. Advanced disease, historically measured in months, has been moved meaningfully — not miraculously — by immunotherapy combinations, whose trial survival curves reset the baseline expectations of this stage for the first time in a generation.

The distribution across those outlooks is the changeable part. Where surveillance programmes function, the early-stage share climbs and with it every aggregate statistic; where they do not, the same biology presents late. Region by region the mix of causes is shifting — viral shares slowly falling under vaccination and antivirals, metabolic shares rising — with the sobering corollary that tomorrow’s typical patient may be outside today’s typical surveillance list. For an individual reader the closing arithmetic is the same as the opening: the factors that most move an HCC prognosis — being in surveillance, imaging on schedule, a complete file reaching an experienced multidisciplinary team early — are administrative before they are medical. This platform exists for the file-and-team part; the six-monthly ultrasound part belongs to the reader and their doctor, starting now.

After curative treatment, life regains its shape with a surveillance rhythm attached: scans and AFP on a schedule that starts three-monthly and relaxes with clean years, lifelong management of the liver disease underneath, and — for transplant recipients — the standard immunosuppression follow-up with one HCC-specific note, that recurrence surveillance continues precisely because selection is imperfect. Survivors of resection and ablation carry a different long-term truth: the remaining liver keeps its risk, so their surveillance never fully ends. It is a manageable tax on a cure, and clinics frame it exactly that way.